Navigation Links
StemCyte Launches New Website

COVINA, Calif., Dec. 7, 2010 /PRNewswire/ -- California-based StemCyte, Inc. announces the launching of its new website,, a comprehensive resource on cord blood banking and its transplant and research initiatives.  In an effort to provide the most comprehensive source of cord blood banking information and education online, StemCyte's new website includes extensive information for customers, physicians, and the general public on the lifesaving medical resource of umbilical cord blood stem cells as well as the potential for regenerative medicine.  

After robust feedback from physicians, clients, researchers and expecting parents during the past year, StemCyte reconstructed its website to provide the quickest and most efficient educational guide to learning about the science and promise of cord blood banking. Free information kits and educational videos are also available to interested parties at

"As one of the world's preeminent cord blood banks and biotherapy companies, we are pleased to offer this critical information and communication tool to our global audience," said Calvin Cole, StemCyte's President, North America.  "We are committed to making available timely and accurate information regarding public and private cord blood banking options, updates on existing therapies and the latest information on cutting-edge biotherapy research."

This website represents StemCyte's latest effort to enhance awareness regarding the science and promise of umbilical cord blood banking and related medical research.

About StemCyte, Inc.

Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world.  StemCyte has supplied over 1,300 cord blood products for over 70 life-threatening diseases to over 200 leading worldwide transplant centers.  StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies.  They are supporting the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and supporting the developments of trials investigating regenerative spinal cord therapies.  They are the only for-profit company contracted by the US Department of HHS to establish a public National Cord Blood Inventory for unrelated transplant units.  Its headquarters are located in Covina, Ca. and Ewing, NJ.  To learn more visit

SOURCE StemCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP)
2. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
3. Wiley-VCH launches new journal Advanced Energy Materials
4. HIPAA 5010 Ready: DST Health Solutions Launches Upgrades of Amisys Advance, PowerMHS, PowerMHC and PowerSTEPP
5. National Science Foundation launches "Innovation Nation"
6. Pfenex Inc. Launches
7. Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
8. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
9. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
10. CoreLab Partners Launches New DXA Imaging Service Offerings
11. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
Breaking Biology News(10 mins):